Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 5/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 3/20 | 0.37 |
| ▸ | HGF | P14210 | 1/20 | 0.37 |
| ▸ | MST1R | Q04912 | 1/20 | 0.37 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | BRS3 | P32247 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3111161 | 0.81 | MET (0.49) | METHGFMST1R | |
| SCHEMBL2379712 | 0.77 | MET (0.58) | MIFMETHGFMST1R | |
| SCHEMBL3117761 | 0.77 | MET (0.39) | MIFMETMST1RJAK1 | |
| SCHEMBL3117756 | 0.74 | KDM1A (0.40) | MIFESR1ESR2METHSD17B1 | |
| SCHEMBL2861659 | 0.72 | ALDH1A1 (0.39) | MIFESR1ESR2HSD17B1 | |
| SCHEMBL3114423 | 0.70 | DRD1 (0.38) | — | |
| SCHEMBL12536543 | 0.69 | DRD1 (0.38) | — | |
| SCHEMBL2855704 | 0.68 | MET (0.58) | METHGFMST1R | |
| SCHEMBL3915728 | 0.68 | MET (0.42) | MIFMETHGFMST1R | |
| SCHEMBL2288757 | 0.68 | MET (0.58) | METHGFMST1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7723330-B2 | Heterobicyclic pyrazole compounds and methods of use | ARRAY BIOPHARMA INC. (US) | 2010-05-25 | — | — | US | disclosed |
| EP-2001880-A2 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | Array Biopharma, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| WO-2007103308-A2 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ROR1, CYP11B1, CYP11B2 | MIF 2408/4885ESR1 2374/4885ESR2 1338/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | MIF 2408/4885ESR1 2374/4885ESR2 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.